The recent outbreaks of avian influenza A (H5N1) virus, its expanding geographic
distribution and its ability to transfer to humans and cause severe infection have raised …

Influenza is a long-standing health problem. For treatment of seasonal flu and possible
pandemic infections, there is a need to develop new anti-influenza drugs that have good …

Emergence of influenza viruses with reduced susceptibility to neuraminidase inhibitors
(NAIs) develops at a low level following drug treatment, and person-to-person transmission …

Influenza viruses are major human pathogens responsible for respiratory diseases affecting
millions of people worldwide and characterized by high morbidity and significant mortality …

The currently circulating H3N2 and H1N1 subtypes of influenza A virus cause a transient,
febrile upper respiratory illness in most adults and children (“seasonal influenza”), but …

Two neuraminidase (NA) inhibitors, zanamivir (Relenza) and oseltamivir phosphate
(Tamiflu), have been licensed for the treatment of and prophylaxis against influenza. In this …

Influenza, a severe viral infection of the respiratory system, is responsible for a significant
morbidity and mortality due to both annual epidemics and unpredictable pandemics. In the …

Covering: 2000 to 2011 The imminent threat of influenza pandemics and repeatedly
reported emergence of new drug-resistant influenza virus strains demonstrate the urgent …

Glycosidases are ubiquitous enzymes involved in a diversity of key biological processes
such as energy uptake or cell wall degradation. The design of specific glycosidase inhibitors …

A bunch of keys, one lock: The multivalent effect in glycosidase inhibition is a new, rapidly
emerging area with exciting potential and scope. This review presents a description of the …